A new uPAR-targeting fluorescent probe for optical guided intracranial surgery in resection of a meningioma-a case report.
Brain surgery
FG001
Fluorescense
Meningiomas
Radicality
uPar
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
22
06
2021
accepted:
27
10
2021
pubmed:
9
11
2021
medline:
27
1
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
Meningiomas are benign lesion although anot insignificant number experiences recurrences despite Simpson grade 1 removal. FG001 is a compound with a fluorophore (ICG) that binds to a urokinase-type plasminogen activator receptor (uPAR) and is currently investigated at our institution in a first-in-human trial. The patient presented with a plausible malignant glioma but proved to be a grade 1 meningioma. FG001 could delineated the tumor not only on the surface but supplementary in the cavity to remove safely the dural attachment. We present FG001 as a new promising tool for improved surgical radicality beyond the intended indication, provided that a prospective validation in a consecutive meningioma cohort demonstrates similar results.
Identifiants
pubmed: 34748074
doi: 10.1007/s00701-021-05051-3
pii: 10.1007/s00701-021-05051-3
doi:
Substances chimiques
Fluorescent Dyes
0
Receptors, Urokinase Plasminogen Activator
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-271Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Bashir A, Binderup T, Vestergaard MB, Broholm H, Marner L, Ziebell M et al (2020) In vivo imaging of cell proliferation in meningioma using 3’-deoxy-3’-[(18)F]fluorothymidine PET/MRI. Eur J Nucl Med Mol Imaging 47(6):1496–1509
doi: 10.1007/s00259-020-04704-2
Bashir A, Larsen VA, Ziebell M, Fugleholm K, Law I (2021) Improved detection of postoperative residual meningioma with [(68)Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph PET scanner. Clin Cancer Res 27(8):2216–2225
doi: 10.1158/1078-0432.CCR-20-3362
Behling F, Hennersdorf F, Bornemann A, Tatagiba M, Skardelly M (2016) 5-Aminolevulinic acid accumulation in a cerebral infarction mimicking high-grade glioma. World Neurosurg 92:586.e5-586.e8
doi: 10.1016/j.wneu.2016.05.009
Christensen A, Juhl K, Persson M, Charabi BW, Mortensen J, Kiss K et al (2017) uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model. Oncotarget 8(9):15407–15419
doi: 10.18632/oncotarget.14282
Gallagher MJ, Jenkinson MD, Brodbelt AR, Mills SJ, Chavredakis E (2016) WHO grade 1 meningioma recurrence: are location and Simpson grade still relevant? Clin Neurol Neurosurg 141:117–121
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17(9):e383–e391
doi: 10.1016/S1470-2045(16)30321-7
Juhl K, Christensen A, Persson M, Ploug M, Kjaer A (2016) Peptide-based optical uPAR imaging for surgery: in vivo testing of ICG-Glu-Glu-AE105. PLoS One 11(2):e0147428
doi: 10.1371/journal.pone.0147428
Juhl K, Christensen A, Rubek N, Karnov KKS, von Buchwald C, Kjaer A (2019) Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white light surgery. Oncotarget 10(59):6308–6316
doi: 10.18632/oncotarget.27220
La Rocca G, Sabatino G, Menna G, Altieri R, Ius T, Marchese E et al (2020) 5-Aminolevulinic acid false positives in cerebral neuro-oncology: not all that is fluorescent is tumor. A case-based update and literature review. World Neurosurg 137:187–193
doi: 10.1016/j.wneu.2020.01.238
Lavrador JP, Kandeel HS, Kalb A, Reisz Z, Al-Sarraj S, Gullan R et al (2020) 5-ALA fluorescence in a WHO grade I papillary glioneuronal tumour: a case report. Acta Neurochir 162(4):813–817
doi: 10.1007/s00701-020-04223-x
Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A (2012) New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nucl Med Biol 39(7):962–969
doi: 10.1016/j.nucmedbio.2012.05.007
Persson M, Juhl K, Rasmussen P, Brandt-Larsen M, Madsen J, Ploug M et al (2014) uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer. Mol Pharm 11(8):2796–2806
doi: 10.1021/mp500177c
Skovgaard D, Persson M, Kjaer A (2017) Urokinase plasminogen activator receptor-PET with (68)Ga-NOTA-AE105: first clinical experience with a novel PET ligand. PET Clin 12(3):311–319
doi: 10.1016/j.cpet.2017.02.003
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401
Wadiura LI, Millesi M, Makolli J, Wais J, Kiesel B, Mischkulnig M et al (2021) High diagnostic accuracy of visible 5-ALA fluorescence in meningioma surgery according to histopathological analysis of tumor bulk and peritumoral tissue. Lasers Surg Med 53(3):300–308
Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D et al (2021) Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol 23(5):783–794